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Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration 
Introduction
Familial hypercholesterolaemia (FH) is a common genetic disorder affecting low-density lipoprotein cholesterol (LDL-C) metabolism, resulting in reduced catabolism of LDL particles and marked elevations in circulating LDL-C [1e4]. If untreated, lifelong exposure to elevated LDL-C results in the development of atherosclerotic lesions early in life and a substantially increased risk of premature cardiovascular disease as compared to the general population [1e6] . In contrast, early detection and effective treatment of FH can result in a significant improvement in clinical outcomes [7, 8] . Despite these compelling data, FH remains largely underdiagnosed with less than 5% of individuals with FH being identified in most regions around the world [1] . Compounding its burden is the observation that FH is undertreated even among those with an established diagnosis [1,9e11] . Moreover, an increase in the evidence-based recommendations for the detection and treatment of patients with FH to reduce cardiovascular risk are needed: whereas the class of recommendations for FH in lipid guidelines is high, the grade of evidence still falls frequently into level C [12] .
Rationale for the EAS FHSC
The reasons behind underascertainment of FH cases are complex. They include an underappreciation of the true prevalence of FH. For instance, the prevalence of heterozygous FH (HeFH) was traditionally considered to be approximately 1:500 individuals [1] . However, in many cases these figures arose from the extrapolation of a limited amount of data from selected populations or specific subgroups to the general population and therefore may be unreliable [13] . By comparison, contemporary clinical and genetic studies suggest that HeFH affects approximately 1:200e250 individuals [1,9,14e17] , implying that up to over 30 million individuals could be affected worldwide [1] . Additionally, the prevalence of FH can vary substantially depending on how FH is defined (i.e. LDL-C threshold only, mutation definition only, both, or clinical score composed of several factors) [17] . Similarly, the observed undertreatment may in part be due to suboptimal use of available therapies for reasons that are unclear but may also include a lack of knowledge about the risks of sub-optimal therapy, concerns about the safety of available therapies, a lack of available therapies, or even a paucity of specialists and established guidelines and standards of care locally. Whilst lipid lowering therapies such as statins are potent, the high lifetime burden of risk from LDL-C elevations means that the impact from any therapeutic intervention is likely to be modest and significantly undermined when delays in the detection of FH and initiation of pharmacological therapies occur [1, 10, 18] . Additionally, the risk of cardiovascular events may also be influenced by additional factors not always completely addressed or recognised, e.g. lipoprotein(a) [19, 20] .
Underappreciation of the prevalence of FH and the adverse consequences of current clinical practice has ultimately resulted in a general lack of health policies aimed specifically at FH and a lack of awareness and education among healthcare professionals and policy-makers [21] . Efforts to tackle the global burden of FH have been hindered by a lack of global cohesion. Firstly, the lack of uniformity among different initiatives, FH definition and ascertainment methods (e.g. opportunistic/cascade/universal screening; clinical/ genetic diagnosis; different clinical criteria; prior absence of a unifying WHO "International Classification of Diseases" code for FH) [1,4,21e26] leads to variability in clinical practice, makes cross-health systems learning difficult, and complicates reliable comparisons and harmonisation efforts. Secondly, data on FH is held in disparate formats across many sites/countries, resulting in fragmentation and lack of harmonised data from different cohorts [21, 26] . A lack of structure and the availability of limited resources have made it hitherto difficult to integrate these cohorts, preventing researchers from scaling up current data and failing to achieve the potential of big data.
The gap in healthcare provision, knowledge and effective strategies requires a collective effort harnessing the combined potential of individual cohorts across the globe. For instance, the potential for global collaborations to inform public health policy reliably about major non-communicable diseases has been successfully demonstrated by international consortia such as the Non-Communicable Diseases consortium or the Emerging Risk Factors collaboration [27e31] . In this context, the European Atherosclerosis Society FH Studies Collaboration (EAS FHSC) is being developed as an ambitious international initiative to gather data derived from FH focused efforts from investigators worldwide [21] . The development of this wide collaborative network of investigators from different regions and countries will support an international large-scale FH registry and improve reliability of data on current clinical practices and corresponding outcomes. A strategic data sharing and integration plan will be implemented to efficiently combine data residing in different sources and formats, bring disparate data silos together, and provide for the first time a unified view of these large combined datasets.
Sharing and pooling the data in a structured systematic approach will allow us to overcome previous barriers and limitations to international comparisons across different cohorts [32e36], such as the heterogeneity, diversity and complexity of the data and standards used. It will align international efforts and help reduce redundant research, avoid duplication of efforts, and reduce costs of research. It will allow us to assess questions which cannot be addressed in individual studies, and provide greater precision in answering these questions than hitherto possible. Moreover, it will unveil additional findings beyond the original hypotheses tested, facilitate exploratory approaches due to the large sample size and generate new hypotheses. It may permit us to detect previously unobservable effects otherwise undetected in limited individual studies. Finally, it will increase the precision of estimates and investigate different patterns, trends and subgroup effects [32e36] . The diversity of the source of these data will also help provide unique and hitherto unavailable insights regarding regional and global variations in clinical practice, which may in turn be due to overt (e.g. health care delivery systems and other patient-, socio-economic-or treatment-related factors) or covert (subtle differences in population genetics) differences across populations.
Thus, information gained from the EAS FHSC will eventually help support and strengthen the evidence-based decision-making process, overcome existing gaps in the management of FH, and inform health policies and clinical guidelines development.
EAS FHSC aims
The EAS FHSC is a global initiative of stakeholders involved in the care of people living with FH that seeks to empower the medical and global community to seek changes in their respective countries or organisations to promote early diagnosis and effective treatment of FH. Specifically, the EAS FHSC aims to:
-Establish a worldwide, standardised registry of patients with FH by bringing together regional/national/international cohorts and registries with access to FH patients. This will allow the collaboration to maximise the exploitation of the data to accurately and reliably investigate (i) the burden of both homozygous FH (HoFH) and HeFH, (ii) how FH is detected and managed, (iii) the clinical consequences of current practice on delivery of care and outcomes, (iv) the factors that influence optimal management and LDL-C target attainment in FH. -Disseminate the information gained from the registry to an international audience including physicians, other healthcare professionals, policy-makers and patients' organizations, to sensitise them to the contemporary burden of FH, encourage open discussion on FH management, promoting a uniform evidence-based standard-of-care, and encourage them to contribute actively to research. -Consolidate a network of investigators interested in FH through which collaborative research and networking on FH can be conducted on a large-scale.
The EAS FHSC registry has been conceived with a longterm strategy in mind, in order to increase the follow-up of patients, including new individuals diagnosed with FH over time, bringing new cohorts into the registry, and take into account temporal trends and changes in clinical practice, so that the findings remain relevant. As such, the project is expected to evolve over time as it will be further developed and expanded: we will continuously employ the best data sharing strategies and optimise the operational protocols based on the experience of the collaboration, number of participants included, results from the first waves of data collated, evolving aims, resources available, and feedback for those utilizing the data and the feedback from the wider medical community. The EAS FHSC protocol is shown in Appendix 1.
EAS FHSC operational structure (Fig. 1)
The EAS FHSC is in the first instance governed by a panel of experts on FH who form the Executive Committee that represents the academic leadership for this initiative (Appendix 2). The Executive Committee represents the core group for overarching management decisions, driving the collaboration, obtaining support and funding to ensure sustainability, and will evaluate the proposals for research, data mining, and expansion of the EAS FHSC.
The Steering Committee represents the advisory committee to provide guidance on the project development. It consists of all those investigators/stakeholders/experts appointed as EAS FHSC National Lead Investigators/ Country-leads (NLI/CLs) for their respective countries/ regions (Appendix 3). The NLI/CLs act as national leaders for the EAS FHSC within their respective countries or regions; as such they coordinate and are responsible for the identification and collaboration from the individual sites within their country/region, encouraging participation of other national physicians and researchers in the collaboration, liaising with relevant societies and patients' organisations, getting appropriate local approvals and permissions as needed, and gathering data from the respective region/ country for transfer to the Coordinating Centre.
The Coordinating Centre is based at the Imperial Centre for Cardiovascular Disease Prevention (ICCP), Imperial College London (ICL), UK. It acts as the central point for data collation, management, standardisation, consolidation, analyses and queries, and it communicates, supports and coordinates the activities of the investigators involved. The Coordinating Centre will ensure the computational tools needed to share, collate and manage the data and will make use of analytical partners (e.g. informatics, biostatistics) to ensure the accurate generation of results.
Stakeholders with access to data on FH patients and data sources are identified through a review (Medline, EMBASE) of relevant published articles and hand search of papers and reports, through contact with national/international scientific societies, and through face-to-face meetings at major conferences. These investigators are approached and invited to join to the EAS FHSC as NLI/ CLs after an initial assessment to establish the scope and characteristics of their data source. This decision is based on a combination of factors including, but not restricted to: estimates of the number of FH patients; information regarding how patients are managed and what key policies/ methods underpinned their management decisions (e.g. whether cascade screening is carried out, whether genetic testing is available, etc.); capacity and resources available to lead EAS FHSC-related activities and coordinate other contributing investigators within their country/region; willingness to participate and conform to the local and project data management safeguard. At the time of the present submission, there were NLI/CLs investigators formally involved from over 50 countries worldwide (Fig. 2) , including those coming directly to the EAS FHSC and from partnerships between the EAS FHSC and other related initiatives, i.e. the 10 Countries Study and the ScreenPro FH programme (Appendix 3).
EAS FHSC methodology
Data from multiple cohorts, registries, databases and collections with access to information on individuals with a clinical and/or genetic diagnosis of HoFH or HeFH will Fig. 1 . EAS FHSC operational/governance structure. be merged and harmonised into the global EAS FHSC registry. Investigators from the local sites will contribute to the FH registry through the NLI/CLs for the corresponding region or country. The latter will transfer and upload the data to the Coordinating Centre to be incorporated into the FH registry (Fig. 3A) .
In order for the investigators to provide reliable data for inclusion into the registry, a set of minimum predefined quality and operational criteria have been laid out (Table 1) , which must be satisfied by individual contributing cohorts. A minimum set of data (core data) are required for inclusion in the registry, comprising general and demographic information, familial and personal cardiovascular history, FH diagnostic criteria, lipid-lowering medication with doses, laboratory lipid profile, and clinical outcomes if follow-up data are available (retrospective or prospective). Where genetic tests are available, these genetic data form part of the core data requested; in case of HoFH, data about LDL-aphaeresis are also collected. Additionally, where available, a number of other parameters of interest will be collected (Appendix 1). Where possible, standardised field definitions will be used and free entry text avoided. Our main long-term outcomes of interest will include all-cause and cardiovascular mortality and fatal/non-fatal cardiovascular events. Nevertheless, given the unique nature of the EAS FHSC database, information on factors such as statin intolerance, incident diabetes, aortic valve/supravalvular disease or cancer will be also sought and analysed. Updates of the shared datasets will be encouraged to be provided within a reasonable time-frame.
For each cohort/dataset a two-stage approach is followed: the first step comprises the collation of the crosssectional and retrospective data readily available; the second stage involves the integration of longitudinal, prospective records and follow-up.
Data management
Management of this large volume of data securely will require the development of an informatics platform, which requires various steps from designing data models, collection, validation, harmonisation, transformation and analysis and reporting.
In the first instance, a secure web portal will be developed for the datasets to be transferred to the Coordinating Centre to provide an automated solution for data transfer, visualization and coordination. Data sharing plans involve instructions to the lead investigators for data to be transferred and data to be collected, updated with feedback for the individual investigators providing the data.
The preliminary data shared will be checked for consistency and accuracy by at least 2 independent investigators of the Coordinating Centre (scientific coordinator, data manager) and any discrepancies will be resolved by raising queries with the individual investigators. After ensuring satisfactory data quality, the information will be saved and harmonised into a bespoke central database (FH Data Warehouse [FHDW]) securely hosted on a university server by the Coordinating Centre, in strict adherence with all data safety protocols and regulatory requirements. The Coordinating Centre, supported by a technical team, will develop cutting edge and artificially intelligent routines incorporating machine learning for automated data cleaning, harmonising and make the data uniform and compatible. The data architecture and platform will support secure incorporation of data irrespective of source or format from multiple global repositories/databases/file systems allowing: data cleaning, validation, quality control and merging into the FHDW; retrospective and ongoing prospective data pooling, harmonisation and analysis. Regular monitoring of various stages of data flow will ensure that appropriate quality standards are maintained and that any deviations from protocols are immediately reported and rectified. The resource will make use of existing standards for wider user acceptance, technical interoperability and scalability. Regular surveys of the users' (i.e. lead investigators') Table 1 EAS FHSC Registry: predefined quality and operational criteria for inclusion/exclusion of data to be shared.
(i)
The data must be in electronic format.
The amount of data shared should be considered enough to add relevant information to the registry. (iii)
The data must have been collected rigorously following a standardised well-designed protocol; inclusion and exclusion criteria must be well defined; FH must be well defined according to accepted criteria and not rely only on self-reported history of FH; any measurements recorded must have been done with validated and standardised methods and devices; standardised definitions should have been used; the data source/participants included should be representative of the target population. (iv)
The parameters recorded must include at least the minimum set of data (core information) as specified in the protocol.
(v)
Local ethical and security aspects must be in place; a data sharing agreement must be signed prior to any data transfer. (vi) Data must conform with the inclusion/exclusion criteria: Inclusion criteria (i) Individuals with a diagnosis of heterozygous or homozygous FH.
-Diagnosis: clinical and/or genetic.
-Also including positive clinical diagnosis with negative genetic test and vice versa.
-In case of clinical diagnosis: -Criteria used: Dutch Lipid Clinics Network, MedPed, Simon-Broome, Japanese criteria, or other to be specified. -Categories of possible, probable and confirmed FH.
(ii) Relatives of index cases without a diagnosis of FH where screening (cascade or other) is carried out. Exclusion criteria -Secondary causes of dyslipidaemia (e.g. untreated hypothyroidism, cholestasis, nephrotic syndrome).
-Where data collation does not conform to the local or country wide standards for anonymised data.
experience will capture their expectations and obtain key suggestions and feedback, allowing appropriate adaptation and improvements of the user/resource interface, enhancing end-user experience for ease-of-use and efficient data management, allowing the resource to properly grow and evolve. The overall structure of the FHDW and platform is shown in Fig. 3B/C . A detailed description is reported in Appendix 1 (protocol).
Analysis plan
After ensuring consistency and compatibility of the information and description of the variables, the data from various providers will be merged and analysed at an individual level as a composite dataset. Where this is not possible, analyses will be undertaken at a country/provider level, by analysing each dataset individually and then pooling the results together.
We will conduct different types of analyses, such as assessing the validity of previous published findings with greater power and precision, conducting alternative analyses of the same data, cross-cohort comparisons, analysing unpublished data (not previously conducted due to low sample size within each separate dataset), conducting exploratory analyses to generate new research hypotheses, etc.
We will analyse the data to address a number of research questions as shown in Table 2 [37, 38] . Standard validated statistical procedures and models for observational studies and weighted meta-analyses (individual participant data meta-analysis where possible; metaanalysis of aggregated data alternatively) will be applied. Statistical methods described in studies such as the Emerging Risk Factors Collaboration [39, 40] or the Non-Communicable Diseases Risk Factor Collaboration [27] will be used where appropriate. After exploratory analyses with description of the variables of interest, cross-sectional analyses and correlates will be performed. Comparisons of continuous parameters will be done with parametric and non-parametric tests as appropriate and categorical variables using Chi-squared test. We will quantify various exposure-outcome associations (unadjusted and adjusted) and epidemiological interactions using standard regression models. Risk prediction models using measures of discrimination (concordance index [Cindex], discrimination measure [D-measure]) and reclassification (net reclassification index [NRI] ) are intended to be performed. Cox proportional hazards regression models stratified by certain variables of interest (e.g. by gender, country, etc.) and KaplaneMeier estimates of survival will be generated where time-to-event data is available.
Measures of heterogeneity and risk of bias (e.g. regression dilution over time) will be applied.
We will account for different variables of interest, carry out appropriate adjustments systematically for potential confounders, consider key subgroups and correct for differences in definitions. Where feasible, reliable, Table 2 EAS FHSC scientific research questions.
The EAS FHSC aims to establish an international registry of studies on FH with a view to better quantifying more reliably than hitherto possible: 1 How FH patients are detected, comparison of different proposed diagnostic criteria, whether current screening strategies for FH are adequate and, if not, what could be done differently to maximise coverage. 2 How patients are managed, treatments offered/advised, how their efficacy is monitored. 3 What proportion of FH patients meet the targets (e.g. LDL-C goals, patients receiving therapy), the impediments in attaining LDL-C goals, the role played by societal factors (such as access to healthcare in different settings and the availability of specialist advice) in enabling treatment to achieve LDL-C goal, the influence of geneedrug interactions in attaining LDL-C goals. 4 Long-term risk of outcomes in patients with FH (including, where possible, estimates of the years lost due to FH), with a special focus on the following end-points:
-Primary end-point 1: the composite of Cardiovascular Disease Events (fatal and non-fatal).
-Primary end-point 2: Cardiovascular mortality.
-Primary end-point 3: All-cause mortality. The following definitions shall apply: (i) Cardiovascular disease events: the composite of fatal and non-fatal coronary heart disease/acute coronary syndrome/myocardial infarction, cardiac sudden death, fatal and non-fatal stroke, transient ischaemic attack, peripheral vascular disease, and revascularization (percutaneous or surgical); (ii) Aortic valve disease: confirmed by any imaging test; (iii) Statin intolerance (clinical and/or biochemical): defined according to the EAS consensus panel [37] ; (iv) New onset of diabetes mellitus: fasting glycaemia >126 mg/dL at least in two separate occasions, glycosylated haemoglobin 6.5% (48 mmol/mol), and/or patient receiving a new prescription of an antidiabetic drug [38] .
and data available we will also try to roughly approximate the prevalence of FH by extrapolating the data to the general population. The different sources of incoming data will also help assess potential variations depending on different geographic settings, including factors such as population genetics, healthcare delivery systems and other patient-, socio-economic-or treatment-related factors.
Following a "database-query" model [34] , investigators involved in the registry will be able to submit research questions they would like to assess through the Coordinating Centre; if the request is deemed to be scientifically relevant by the Executive Committee and considered feasible by the Coordinating Centre, the latter will construct and run the analyses and return the results to the requester.
Ethics, security and regulatory considerations
This project and related research will be conducted in accordance with the principles of the Declaration of Helsinki. Where required, approval from the corresponding ethical and/or research committees and informed consent from participants will be requested by the investigators to collect, transfer and share the data. Data sharing agreements will be executed between the NLI/CLs sharing the data and the Coordinating Centre as the recipient of the data (Appendix 4).
The investigators and the Coordinating Centre will use all reasonable safeguards in connection with any transfer, communication or remote access connectivity involving the data. A secure web portal will be developed as a means for data entry/coordination and controlled environment. Only de-identified, pseudo-anonymised data will be collected, and removal of identifiers, replacement of dates with time intervals where possible, and categorization of several characteristics will be performed. A Global Unique Identifier will be assigned to each subject enabling investigators to follow their own subjects over time.
Data servers physically hosted by ICL will be encrypted to standards utilizing appropriate infrastructure; the database will be configured to be accessed only from approved terminals/computers. The data storage and handling will be compliant with the European Data Protection Act.
Dissemination and communication
The dissemination and exploitation plan will aim to maximise the spread of the results within a wide, large and diverse audience and to make the most of the information gained from the global FH registry. The means of dissemination will be varied and tailored to the target audience, making use of the different resources available (including eHealth resources) in order to reach and impact stakeholders involved in the care of FH patients at multiple levels. The target audience will include physicians and other healthcare providers, investigators, FH patients and their relatives through the patients' organisations, policymakers, and, in general, the entire medical community. As all of these groups are potential users of the information generated we will aim to reach them all to ensure that the state-of-the-art information released is utilized to reduce gaps in knowledge and improve clinical practice for FH patients. The dissemination plan will include a number of components, such as publication of results in the form of reports and scientific articles in peer-reviewed high-impact international journals; communication of results at major conferences; academic dissemination; web and social media dissemination; press releases; engagement with patients' organisations; where possible, engagement with policy-makers/health authorities; networking events (meetings, web forum).
Conclusions
The EAS FHSC initiative was formally launched during the 83rd EAS Congress in March 2015. Since then, a vast network of collaborators have formally committed themselves to join the EAS FHSC initiative; it is expected that other regions may follow suit as the project evolves, making the EAS FHSC an internationally leading registry for FH at the forefront of FH research.
The EAS FHSC initiative represents an excellent opportunity to integrate efforts across the world to tackle the global burden of FH. The large, cross-national, robust information generated from the FH registry will help narrow gaps in knowledge, inform the medical community about real-world and best practices, assist in clinical trials design, and support clinical guidelines and policy development. Ultimately, it will help prevent adverse outcomes and improve care of FH patients.
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